November 14, 2025: MaaT Pharma announces the successful completion of its Global Offering of €9.1 million - MaaT Pharma
Summary
MaaT Pharma completed a €9.1 million global offering through a private placement and a retail offering. The company plans to use the proceeds to support commercialization preparations for Xervyteg in Europe, advance its MaaT033 clinical program, and continue FDA discussions for a U.S. pivotal study. The financing extends the company’s cash runway and helps satisfy conditions for an additional EIB tranche. The release also notes ongoing partnership and additional financing options that could further support development and commercialization.
Funding
Amount
$9.8M
Total raised
Date
November 14, 2025
Announcement date
Investors
Invus, Biocodex
Lead investors
Company
maatpharma.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected